

FOR IMMEDIATE RELEASE

Contact: John Hawkins
Executive Vice President
MedPointe Inc.
(732) 564-2233
jhawkins@medpointepharma.com
www.medpointepharma.com

MEDPOINTE AND BIOVAIL SIGN CO-PROMOTION DEAL

MedPointe to Provide Third Position Details, Sample Drops of Biovail's Zovirax[®]

Somerset, NJ – October 4, 2005 – MedPointe Inc. reached agreement with Biovail Corporation (NYSE, TSX: BVF) today on a new co-promotion opportunity.

Under the terms of the agreement, MedPointe has agreed to promote Biovail's Zovirax[®] (acyclovir) Cream and Zovirax[®] (acyclovir) Ointment. Zovirax[®] is a leading brand in the topical treatment of herpes simplex viruses. The co-promotion will complement Biovail's efforts in the offices of OB-GYN and Dermatology specialists. MedPointe will be focusing on primary care offices. Each company will have separate physician targets and non-overlapping call decks.

The new collaboration will continue to support MedPointe's efforts in the primary-care sector and provide additional revenue to promote the Company's key brands.

Zovirax[®] Cream 5% is indicated for the treatment of recurrent herpes labialis (cold sores) in adults and adolescents (12 years of age and older). The most common adverse reactions at the site of topical application were dry lips, desquamation, dryness of skin, cracked lips, burning skin, pruritus, flakiness of skin, and stinging of skin; each event occurred in less than 1% of patients receiving Zovirax[®] Cream and vehicle. Some cases of angioedema, contact dermatitis, and inflammation at the application site have been reported. Zovirax[®] Cream does not prevent transmission of HSV infections, and its effect has not been established in immunocompromised patients. Zovirax[®] Cream is available by prescription only. Please see full Prescribing Information.

Zovirax[®] Ointment 5% is indicated in the management of initial genital herpes and in limited non-life-threatening mucocutaneous herpes simplex virus infections in immunocompromised patients. Mild pain (including transient burning, stinging, and itching) has been reported with no significant difference between Zovirax[®] Ointment and placebo. Zovirax[®] Ointment does not prevent transmission of HSV infections. Zovirax[®] Ointment is available by prescription only. Please see full Prescribing Information.

MedPointe Inc. is a privately held specialty pharmaceutical company located at 265 Davidson Avenue, Suite 300, Somerset, New Jersey, 08873-4120; 732-564-2200. Backed by private equity investors, including The Carlyle Group and The Cypress Group, MedPointe specializes in respiratory, allergy, central nervous system, and pediatric products. The Company maintains a manufacturing facility in Decatur, IL. For more information on MedPointe, visit www.medpointepharma.com.

####